Split History
ETFs Holding XFOR »    XFOR Historical Stock Prices »



Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
X4 PHARMACEUTICALS is a biopharmaceutical company. Co.'s primary clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4, that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, mavorixafor has the potential to provide therapeutic benefit across a variety of neutropenic disorders, including Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare, primary immunodeficiency. Co. is also developing mavorixafor in a Phase 2 clinical trial in people with certain neutropenic disorders. According to our XFOR split history records, X4 Pharmaceuticals has had 1 split.
XFOR split history picture
X4 Pharmaceuticals (XFOR) has 1 split in our XFOR split history database. The split for XFOR took place on March 14, 2019. This was a 1 for 6 reverse split, meaning for each 6 shares of XFOR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as X4 Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the XFOR split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into X4 Pharmaceuticals shares, starting with a $10,000 purchase of XFOR, presented on a split-history-adjusted basis factoring in the complete XFOR split history. XFOR split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 11/17/2017
End date: 04/26/2024
Start price/share: $83.58
End price/share: $1.17
Dividends collected/share: $0.00
Total return: -98.61%
Average Annual Total Return: -48.49%
Starting investment: $10,000.00
Ending investment: $139.40
Years: 6.44
Date Ratio
03/14/20191 for 6
XFOR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

XOMA Split History
XRAY Split History
XTNT Split History
YMTX Split History
YTEN Split History
ZBH Split History
ZGNX Split History
ZLCS Split History
ZSAN Split History
ZVSA Split History

Also explore: XFOR shares outstanding history

Email EnvelopeFree XFOR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Recon Technology, Ltd. (RCON)
iSun, Inc. (ISUN)
Avenue Therapeutics, Inc. (ATXI)
Bakkt Holdings, Inc. (BKKT)
Applied DNA Sciences, Inc. (APDN)
Cidara Therapeutics, Inc. (CDTX)
Smart for Life, Inc. (SMFL)
Windtree Therapeutics, Inc. (WINT)
Golden Sun Health Technology Group Limited (GSUN)
Zapp Electric Vehicles Group Limited (ZAPP)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

XFOR Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.